CN204275064U - Urapidil effervescent tablet - Google Patents
Urapidil effervescent tablet Download PDFInfo
- Publication number
- CN204275064U CN204275064U CN201420713336.8U CN201420713336U CN204275064U CN 204275064 U CN204275064 U CN 204275064U CN 201420713336 U CN201420713336 U CN 201420713336U CN 204275064 U CN204275064 U CN 204275064U
- Authority
- CN
- China
- Prior art keywords
- urapidil
- acid source
- effervescent tablet
- layer
- capsule skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a kind of urapidil effervescent tablet, comprise acid source layer, urapidil medicine layer and alkali source layer from inside to outside successively, described acid source layer comprises acid source utricule; Acid source utricule comprises the first capsule skin of acid source and parcel acid source; First capsule Intradermal is filled with alkali source granule.Urapidil effervescent tablet of the present utility model, stable in properties, can not affect the stability of effervescent tablet because of the acid source moisture absorption; When needs effervescent, rate of effervescence is fast; Energy secondary effervescent, effervescent is abundant.
Description
Technical field
This utility model belongs to drug world, particularly a kind of urapidil effervescent tablet.
Technical background
Urapidil is mainly used in hypertensive treatment, and its preparation has urapidil injection, urapidil sheet, urapidil capsule etc. at present.The oral formulations taste of injection use inconvenience, liquid preparation poor stability, other series is not good.Effervescent tablet can solve the problem of existing preparation well, onset is rapid, bioavailability is high, and mouthfeel is good, be particularly suitable for child, old people garment is used, but find no precedent urapidil being made effervescent tablet in prior art, and most of effervescent tablet due to the acid source easy moisture absorption, quality is unstable.In order to solve the problem of the easy moisture absorption of acid source, be generally adopt soda acid to granulate respectively, remix tabletting after soda acid granule, object reduces the contact area of soda acid granule, improves the stability of sample; But the sample stability of preparation is still not high like this.
Utility model content
The purpose of this utility model is to provide and a kind ofly effectively can solves the easy moisture absorption of acid source and cause the urapidil effervescent tablet of the problem of effervescent tablet instability.
Specific description is done to content of the present utility model below:
Urapidil effervescent tablet of the present utility model, urapidil effervescent tablet comprises acid source layer, urapidil medicine layer and alkali source layer from inside to outside successively, and described acid source layer comprises acid source utricule; Acid source utricule comprises the first capsule skin of acid source and parcel acid source; First capsule Intradermal is filled with alkali source granule.
Acid source layer is arranged on innermost layer, prevents its moisture absorption; Be wrapped in by acid source in the first capsule skin, alkali source is particles filled in the first capsule Intradermal simultaneously, by soda acid source material separately, when needing effervescent, acid source is easy to mix with alkali source material and effervescent, can realize the effect of secondary effervescent, reach good effervescent effect.
Urapidil effervescent tablet of the present utility model, is also provided with the second capsule skin between acid source layer and urapidil medicine layer, the second capsule Intradermal is filled with moisture absorption granule.
The setting of moisture absorption granule in second capsule skin, can stop the moisture absorption of soda acid source material further, ensures the stability of urapidil effervescent tablet.
Urapidil effervescent tablet of the present utility model, is also provided with the 3rd capsule skin between urapidil medicine layer and alkali source layer; Acid source granule is filled with in 3rd capsule skin.
The setting of acid source granule in 3rd capsule skin, can act on mutually with alkali source layer, and form an effervescent, rate of effervescence is fast.
Urapidil effervescent tablet of the present utility model, urapidil medicine layer is eight flap-type structures, and two adjacent lobes are filled with urapidil utricule and urapidil granule respectively, and urapidil utricule is the utricule being filled with urapidil liquid; Urapidil granule is slow-release micro-pill or sustained-release micro-spheres.
Eight flap-type structures improve the contact area of acid source layer and alkali source layer, after effervescent, make it disperse evenly, be filled with urapidil liquid in urapidil utricule, can absorb fast, rapid-onset; Urapidil granule plays the effect of slow release.
Urapidil effervescent tablet of the present utility model, the 3rd capsule skin is provided with equally distributed groove.
The setting of groove, when needs effervescent, can accelerate rate of effervescence, makes effervescent tablet quick acting further.
Urapidil effervescent tablet of the present utility model, alkali source layer comprises alkali source material and the 4th capsule skin, and alkali source material is filled in groove, and the 4th capsule suitcase is wrapped in the skin of the 3rd capsule skin and is fixed the alkali source material be filled in groove.
Alkali source layer be arranged on outermost layer serve in and the effect of gastric acid, can available protecting stomach; Also itself and acid source are separated simultaneously, improve urapidil effervescent tablet stability; The alkali source material of alkali source layer can play the effect of first time effervescent with the acid source granule in the 3rd capsule skin.
The beneficial effect of urapidil effervescent tablet of the present utility model is: urapidil effervescent tablet of the present utility model, stable in properties, can not affect the stability of effervescent tablet because of the acid source moisture absorption; When needs effervescent, rate of effervescence is fast, can secondary effervescent, and effervescent is abundant.
Accompanying drawing explanation
Fig. 1 is the perspective view of urapidil effervescent tablet of the present utility model;
Fig. 2 is the A-A profile of urapidil effervescent tablet in embodiment 1;
Fig. 3 is the A-A profile of urapidil effervescent tablet in embodiment 2;
Fig. 4 is the A-A profile of urapidil effervescent tablet in embodiment 3;
Fig. 5 is the A-A profile of urapidil effervescent tablet in embodiment 4;
Fig. 6 is the A-A profile of urapidil effervescent tablet in embodiment 5.
Detailed description of the invention
Below in conjunction with embodiment, the utility model is described in further detail:
Embodiment 1
Urapidil effervescent tablet of the present utility model, as shown in Figure 1, 2,1 is acid source layer, and 11 is acid source utricule, and 111 is acid source, and 112 is the first capsule skin, and 113 is alkali source granule; 2 is urapidil medicine layer; 3 is alkali source layer.
Urapidil effervescent tablet of the present utility model, as shown in Figure 1, 2, urapidil effervescent tablet comprises acid source layer 1, urapidil medicine layer 2 and alkali source layer 3 from inside to outside successively, and acid source layer 1 comprises acid source utricule 11; Acid source utricule 11 comprises the first capsule skin 112 of acid source 111 and parcel acid source; Alkali source granule 113 is filled with in first capsule skin 112.
Embodiment 2
Urapidil effervescent tablet of the present utility model, as shown in Figure 1,3,1 is acid source layer, and 11 is acid source utricule, and 111 is acid source, and 112 is the first capsule skin, and 113 is alkali source granule; 2 is urapidil medicine layer; 3 is alkali source layer; 4 is the second capsule skin; 41 is moisture absorption granule.
Urapidil effervescent tablet of the present utility model, as shown in Figure 1,3, except from embodiment 1 exist following different except, all the other are all identical: be also provided with between acid source layer 1 and urapidil medicine layer 2 in second capsule skin 4, second capsule skin 4 and be filled with moisture absorption granule 41.
Embodiment 3
Urapidil effervescent tablet of the present utility model, as shown in Fig. 1,4,1 is acid source layer, and 11 is acid source utricule, and 111 is acid source, and 112 is the first capsule skin, and 113 is alkali source granule; 2 is urapidil medicine layer; 3 is alkali source layer; 4 is the second capsule skin; 41 is moisture absorption granule; 5 is the 3rd capsule skin, and 51 is acid source granule.
Urapidil effervescent tablet of the present utility model, as shown in Fig. 1,4, except from embodiment 2 exist following different except, all the other are all identical: be also provided with the 3rd capsule skin 5 between urapidil medicine layer 2 and alkali source layer 3; Acid source granule 51 is filled with in 3rd capsule skin 5.
Embodiment 4
Urapidil effervescent tablet of the present utility model, as shown in Figure 1,5,1 is acid source layer, and 11 is acid source utricule, and 111 is acid source, and 112 is the first capsule skin, and 113 is alkali source granule; 2 is urapidil medicine layer, and 21 is urapidil utricule, and 22 is urapidil granule; 3 is alkali source layer; 4 is the second capsule skin; 41 is moisture absorption granule; 5 is the 3rd capsule skin, and 51 is acid source granule.
Urapidil effervescent tablet of the present utility model, as shown in Figure 1,5, except from embodiment 3 exist following different except, all the other are all identical: urapidil medicine layer 2 is eight flap-type structures, two adjacent lobes are filled with urapidil utricule 21 and urapidil granule 22 respectively, and urapidil utricule 21 is for being filled with the utricule of urapidil liquid; Urapidil granule 22 is slow-release micro-pill or sustained-release micro-spheres.
Embodiment 5
Urapidil effervescent tablet of the present utility model, as a shown in Figure 6,1 is acid source layer, and 11 is acid source utricule, and 111 is acid source, and 112 is the first capsule skin, and 113 is alkali source granule; 2 is urapidil medicine layer, and 21 is urapidil utricule, and 22 is urapidil granule; 3 is alkali source layer, and 31 is alkali source material, and 32 is the 4th capsule skin; 4 is the second capsule skin; 41 is moisture absorption granule; 5 is the 3rd capsule skin, and 51 is acid source granule.
Urapidil effervescent tablet of the present utility model, as a shown in Figure 6, except from embodiment 4 exist following different except, all the other are all identical: the 3rd capsule skin 5 is provided with equally distributed groove; Alkali source layer 3 comprises alkali source material 31 and the 4th capsule skin 32, and alkali source material 31 is filled in groove, and the 4th capsule skin 32 is wrapped in the skin of the 3rd capsule skin 5 and is fixed the alkali source material 31 be filled in groove.
The beneficial effect of urapidil effervescent tablet of the present utility model is: urapidil effervescent tablet of the present utility model, stable in properties, can not affect the stability of effervescent tablet because of the acid source moisture absorption; When needs effervescent, rate of effervescence is fast; Energy secondary effervescent, effervescent is abundant.
Claims (6)
1. a urapidil effervescent tablet, it is characterized in that, described urapidil effervescent tablet comprises acid source layer (1), urapidil medicine layer (2) and alkali source layer (3) from inside to outside successively, and described acid source layer (1) comprises acid source utricule (11); Described acid source utricule (11) comprises the first capsule skin (112) of acid source (111) and parcel acid source; Alkali source granule (113) is filled with in described first capsule skin (112).
2. urapidil effervescent tablet according to claim 1, it is characterized in that, also be provided with the second capsule skin (4) between described acid source layer (1) and urapidil medicine layer (2), in described second capsule skin (4), be filled with moisture absorption granule (41).
3. urapidil effervescent tablet according to claim 2, is characterized in that, is also provided with the 3rd capsule skin (5) between described urapidil medicine layer (2) and alkali source layer (3); Acid source granule (51) is filled with in described 3rd capsule skin (5).
4. urapidil effervescent tablet according to claim 3, it is characterized in that, described urapidil medicine layer (2) is eight flap-type structures, two adjacent lobes are filled with urapidil utricule (21) and urapidil granule (22) respectively, and described urapidil utricule (21) is for being filled with the utricule of urapidil liquid; Described urapidil granule (22) is slow-release micro-pill or sustained-release micro-spheres.
5. urapidil effervescent tablet according to claim 4, is characterized in that, described 3rd capsule skin (5) is provided with equally distributed groove.
6. urapidil effervescent tablet according to claim 5, it is characterized in that, described alkali source layer (3) comprises alkali source material (31) and the 4th capsule skin (32), described alkali source material (31) is filled in described groove, and described 4th capsule skin (32) is wrapped in the skin of described 3rd capsule skin (5) and is fixed the alkali source material (31) be filled in described groove.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420713336.8U CN204275064U (en) | 2014-11-24 | 2014-11-24 | Urapidil effervescent tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420713336.8U CN204275064U (en) | 2014-11-24 | 2014-11-24 | Urapidil effervescent tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204275064U true CN204275064U (en) | 2015-04-22 |
Family
ID=52858270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420713336.8U Expired - Fee Related CN204275064U (en) | 2014-11-24 | 2014-11-24 | Urapidil effervescent tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204275064U (en) |
-
2014
- 2014-11-24 CN CN201420713336.8U patent/CN204275064U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2443793B (en) | Product, method of manufacture and use | |
| CN103005262A (en) | Donkey-hide-gelatin brown sugar and preparation method thereof | |
| CN204275066U (en) | Doxofylline effervescent tablet | |
| CN102475175A (en) | Anemopyretic cold alleviating tea | |
| CN204275064U (en) | Urapidil effervescent tablet | |
| CN204364476U (en) | Ambroxol effervescent tablet | |
| CN204275065U (en) | Xiaoyin effervescent tablet | |
| CN102925322A (en) | Bombyx mori health-preserving wine and manufacturing method thereof | |
| CN103798424A (en) | Chuzhou chrysanthemum tea chewable tablet and preparation method thereof | |
| CN204246530U (en) | Azithromycin effervescent tablet | |
| CN102742695A (en) | Myrsinaceae health-care tea | |
| CN105495595A (en) | Pearl containing buccal tablets and preparation method | |
| CN103239373A (en) | Wild rose moisturizing cream | |
| CN103749842B (en) | Healthcare citronella tea | |
| CN106578812A (en) | Solid health-caring beverage and preparation method of same | |
| CN204275071U (en) | Double coptis effervescent tablets | |
| CN103734639A (en) | Preparation method of chewable black garlic tablet | |
| CN203884621U (en) | Effervescent tablet containing agrocybe cylindracea compositions | |
| CN203861610U (en) | Compound Platycodon grandiflorum anti-cough tablet | |
| CN103053753B (en) | Swamp cudweed herb healthcare tea | |
| CN102525950B (en) | Method for preparing pellets of Se-polysaccharides in Codonopsis pilosula | |
| CN205093529U (en) | Honey pollen tablet in compound hole in area | |
| CN204364477U (en) | Reduce the Chinese medicine effervescent tablet of blood fat | |
| CN101455338A (en) | Ginseng fruit nutrient effervescence tablet and manufacture method thereof | |
| CN205093527U (en) | Double -colored circular honey health care piece of haplopore |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 Termination date: 20171124 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |